ASCO 2022
ASCO 2022
American Society of Clinical Oncology 2022 Annual Meeting
GU Oncology Now EditorsJournal | July 27, 2022
Prostate cancer highlights from ASCO 2022 are discussed, including the ENZAMET trial design and TheraP trial data.
Read More
Catherine H. Marshall, MD, MPHJournal | July 27, 2022
Highlights from ASCO 2022, including the role of doublet therapy (ADT combined with a novel oral antiandrogen drug).
Vanessa IraASCO 2022 | June 7, 2022
The findings are notable for a patient population that has limited treatment options.
Vanessa IraASCO 2022 | June 7, 2022
Cell-free DNA (cfDNA) methylation may be used to predict treatment response in patients with muscle-invasive bladder cancer.
Vanessa IraASCO 2022 | June 7, 2022
The TheraP ANZUP 1603 trial showed both options were suitable for men with mCRPC.
Vanessa IraASCO 2022 | June 7, 2022
The treatment was also compared to an active comparator of non-steroidal anti-androgen.
Vanessa IraASCO 2022 | June 3, 2022
Researchers hypothesized that switch maintenance therapy with the TKI would improve outcomes for the metastatic disease.
Vanessa IraASCO 2022 | June 3, 2022
The data were from a randomized phase-2 study assessing new treatment combinations in patients with advanced clear cell RCC.
Vanessa IraASCO 2022 | June 3, 2022
The findings could lead to improved outcomes in men with PSMA PET-positive mCRPC.
Vanessa IraASCO 2022 | June 3, 2022
Researchers found it had clinical efficacy regardless of patients' prior treatment or standard of care chosen.
Vanessa IraASCO 2022 | June 3, 2022
The results mean that progression-free survival endpoints could be used to expediate phase-3 clinical trials.
Vanessa IraASCO 2022 | June 3, 2022
The rate of relapses occurring 2 or 5 years after disease-free survival is low among testicular cancer patients, study finds.
Vanessa IraASCO 2022 | June 3, 2022
The association between health-related quality of life and clinical outcomes was identified in the CheckMate 214 study.
Vanessa IraASCO 2022 | June 3, 2022
There were previously no data comparing second-generation ARIs with first-generation ARIs.
Advertisement
Advertisement